Core Viewpoint - The market anticipates that Keysight (KEYS) will report a year-over-year increase in earnings driven by higher revenues when it releases its quarterly results for the period ending April 2025 [1][2]. Earnings Expectations - Keysight is expected to report quarterly earnings of $1.65 per share, reflecting a year-over-year increase of 17% [3]. - Revenue projections stand at $1.28 billion, which is a 5% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.34% over the last 30 days, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Keysight is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.37%, suggesting a bearish outlook from analysts [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - In the last reported quarter, Keysight exceeded the expected earnings of $1.69 per share by delivering $1.82, resulting in a surprise of +7.69% [12]. - Over the past four quarters, Keysight has consistently beaten consensus EPS estimates [13]. Conclusion - While Keysight does not currently appear to be a strong candidate for an earnings beat, investors should consider other influencing factors when making investment decisions ahead of the earnings release [16].

Core Insights - Dianthus Therapeutics, Inc. reported a quarterly loss of $0.82 per share, which was better than the Zacks Consensus Estimate of a loss of $0.86, but worse than the loss of $0.54 per share from the previous year, indicating a 51.85% increase in loss year-over-year [1] - The company achieved revenues of $1.16 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.13% and showing a 33.33% increase from $0.87 million in the same quarter last year [2] - The stock has underperformed the market, losing approximately 10.1% since the beginning of the year compared to the S&P 500's decline of 3.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.93 on revenues of $1.36 million, while for the current fiscal year, the estimate is -$3.38 on revenues of $5.17 million [7] - The estimate revisions trend for Dianthus Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Dianthus Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - The market anticipates a year-over-year decline in earnings for ICL Group despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - ICL Group is expected to report quarterly earnings of $0.08 per share, reflecting an 11.1% decrease year-over-year, while revenues are projected to be $1.77 billion, a 2% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 11.11% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for ICL Group is higher than the consensus estimate, resulting in an Earnings ESP of +12.50%, indicating a likelihood of beating the consensus EPS estimate [10][11]. Historical Performance - ICL Group has consistently beaten consensus EPS estimates, achieving a surprise of +33.33% in the last reported quarter and surpassing estimates in all of the last four quarters [12][13]. Conclusion - ICL Group is positioned as a strong candidate for an earnings beat, but investors should consider additional factors influencing stock performance beyond earnings results [14][16].

Oportun Financial Corporation (OPRT) reported $235.9 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 5.8%. EPS of $0.40 for the same period compares to $0.09 a year ago.The reported revenue represents a surprise of +2.98% over the Zacks Consensus Estimate of $229.08 million. With the consensus EPS estimate being $0.09, the EPS surprise was +344.44%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they co ...

Core Viewpoint - Wall Street anticipates flat earnings for Flowers Foods (FLO) in the upcoming quarter, with revenues expected to increase slightly, but actual results will significantly influence stock price movements [1][3]. Earnings Expectations - Flowers Foods is projected to report earnings of $0.38 per share, unchanged from the previous year, with revenues estimated at $1.6 billion, reflecting a 1.7% increase year-over-year [3]. - The consensus EPS estimate has been revised down by 0.33% over the last 30 days, indicating a bearish sentiment among analysts [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Flowers Foods is lower than the consensus estimate, resulting in an Earnings ESP of -1.06% [10][11]. - The stock currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Flowers Foods exceeded earnings expectations by delivering $0.22 per share against an expected $0.21, resulting in a surprise of +4.76% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - Despite the potential for an earnings beat, Flowers Foods does not appear to be a strong candidate for exceeding expectations based on current estimates and rankings [16].

QXO, Inc. (QXO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.02, delivering a surprise of 60%.Over the last four quarters, the company has surpassed consens ...

Core Insights - Alliant Energy reported quarterly earnings of $0.83 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.62 per share a year ago, resulting in an earnings surprise of 45.61% [1] - The company generated revenues of $1.13 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.17% and up from $1.03 billion year-over-year [2] - Alliant Energy's stock has increased approximately 4.5% since the beginning of the year, contrasting with a -4.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.58 on revenues of $1.02 billion, and for the current fiscal year, it is $3.22 on revenues of $4.29 billion [7] - The estimate revisions trend for Alliant Energy is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Utility - Electric Power industry is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - MBIA reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, but an improvement from a loss of $0.52 per share a year ago, indicating an earnings surprise of -128.57% [1] - The company posted revenues of $27 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 28.57%, although this was a decline from $32 million in revenues a year ago [2] - MBIA shares have declined approximately 28.2% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $21 million, and for the current fiscal year, it is -$0.25 on revenues of $84 million [7] - The Zacks Industry Rank for Insurance - Multi line is in the top 30% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] 分组3 - The estimate revisions trend for MBIA is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - VAREX IMAGING reported $212.9 million in revenue for the quarter ended March 2025, a year-over-year increase of 3.3% [1] - The EPS for the same period was $0.26, compared to $0.16 a year ago, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $206.83 million by 2.93%, and the EPS surprised by 85.71% against the consensus estimate of $0.14 [1] Group 2 - VAREX IMAGING's Industrial revenues were $59.10 million, slightly below the estimated $59.12 million, reflecting a 3% year-over-year change [4] - Medical revenues reached $153.80 million, surpassing the average estimate of $147.36 million, marking a 3.4% increase year-over-year [4] - Gross profit for Industrial was $20.80 million, exceeding the estimated $19.64 million, while Medical gross profit was $55.90 million, above the estimated $48.61 million [4] Group 3 - VAREX IMAGING shares have returned -6% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Company Performance - 10x Genomics reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.45, and an improvement from a loss of $0.50 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of $154.88 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 16.24%, and up from $141.01 million in the same quarter last year [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - 10x Genomics shares have declined approximately 42.1% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $146.51 million, and for the current fiscal year, it is -$1.47 on revenues of $609.56 million [7] Industry Outlook - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of 10x Genomics may be influenced by the overall industry outlook, as empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]